Literature DB >> 19208795

A systems perspective of ras signaling in cancer.

Edward C Stites1, Kodi S Ravichandran.   

Abstract

The development of cancer reflects the complex interactions and properties of many proteins functioning as part of large biochemical networks within the cancer cell. Although traditional experimental models have provided us with wonderful insights on the behavior of individual proteins within a cancer cell, they have been deficient in simultaneously keeping track of many proteins and their interactions in large networks. Computational models have emerged as a powerful tool for investigating biochemical networks due to their ability to meaningfully assimilate numerous network properties. Using the well-studied Ras oncogene as an example, we discuss the use of models to investigate pathologic Ras signaling and describe how these models could play a role in the development of new cancer drugs and the design of individualized treatment regimens.

Entities:  

Mesh:

Year:  2009        PMID: 19208795     DOI: 10.1158/1078-0432.CCR-08-2753

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

Review 2.  PI3K: A Crucial Piece in the RAS Signaling Puzzle.

Authors:  Agata Adelajda Krygowska; Esther Castellano
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

3.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

Review 4.  MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.

Authors:  Saswati Karmakar; Garima Kaushik; Ramakrishna Nimmakayala; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Semin Cancer Biol       Date:  2017-12-02       Impact factor: 15.707

5.  Independent and core pathways in oncogenic KRAS signaling.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Expert Rev Proteomics       Date:  2016-07-18       Impact factor: 3.940

6.  A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Authors:  Khalid Jazieh; Julian Molina; Jacob Allred; Jun Yin; Joel Reid; Matthew Goetz; Vun-Sin Lim; Scott H Kaufmann; Alex Adjei
Journal:  Invest New Drugs       Date:  2018-08-31       Impact factor: 3.651

7.  The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy.

Authors:  Fan Liang; Chunxia Ren; Jingshu Wang; Shuoer Wang; Lina Yang; Xianghui Han; Yaping Chen; Guoqing Tong; Gong Yang
Journal:  Oncogenesis       Date:  2019-10-09       Impact factor: 7.485

8.  Akt Inhibition Enhanced the Growth Inhibition Effects of Low-Dose Heavy-Ion Radiation via the PI3K/Akt/p53 Signaling Pathway in C6 Glioblastoma Cells.

Authors:  Ke Huang; Wei Zhao; Xuqiao Wang; Yingfei Qiu; Zelin Liu; Rui Chen; Wei Liu; Bin Liu
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

9.  Role of H-Ras/ERK signaling in carbon nanotube-induced neoplastic-like transformation of human mesothelial cells.

Authors:  Warangkana Lohcharoenkal; Liying Wang; Todd A Stueckle; Jino Park; William Tse; Cerasela-Zoica Dinu; Yon Rojanasakul
Journal:  Front Physiol       Date:  2014-06-12       Impact factor: 4.566

10.  Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.

Authors:  Edward C Stites; Andrey S Shaw
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.